Lenvatinib Plus PD-1 Antibody for Unresectable ICC
Status:
Suspended
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with
PD-1 antibody for patients with unresectable intrahepatic cholangiocarcinoma.